Status of Immune Oncology: Challenges and Opportunities
Author:
Publisher
Springer New York
Link
http://link.springer.com/content/pdf/10.1007/978-1-4939-9773-2_1
Reference81 articles.
1. Salk J (1969) Immunological paradoxes: theoretical considerations in the rejection or retention of grafts, tumors, and normal tissue. Ann N Y Acad Sci 164(2):365–380
2. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (2018) Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 6(1):8
3. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116–129
4. Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caraco C et al (2018) Perspectives in melanoma: meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy). J Transl Med 16(1):207
5. Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B et al (2018) Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29–30 November, 2017, Naples, Italy). J Immunother Cancer 6(1):69
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Single-cell technologies uncover intra-tumor heterogeneity in childhood cancers;Seminars in Immunopathology;2023-01
2. Overview of Immunohistochemistry Assessment of Cancer-Related Predictive Biomarkers and Common Genetic Alterations;Handbook of Practical Immunohistochemistry;2022
3. Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy;Journal of Experimental & Clinical Cancer Research;2021-10-16
4. Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated Immunosuppression in Breast Carcinomas;Cancer Discovery;2020-12-16
5. Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges;Journal for ImmunoTherapy of Cancer;2020-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3